Issue 1, 2013

Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling

Abstract

We discovered a novel molecular framework 4 containing a heterobiaryl pyrazolopyridine moiety as a selective FLT3 kinase inhibitor from phenotype-based viability profiling. Compound 4g showed outstanding selectivity in cellular cytotoxicity against MV-4-11 leukemic cells via the induction of apoptosis. The hypothesis-driven deconvolution elucidated that compound 4g selectively blocked the phosphorylation of FLT3 and its downstream effectors, such as ERK and STAT5, only in MV-4-11 cells. The inhibitory effect of 4g on in vitro enzyme function and FLT3 phosphorylation in cells proved that FLT3 kinase is a direct molecular target of 4g. Finally, the kinase activity profiling of 4g verified its excellent selectivity toward FLT3 over 40 representative kinases, including the receptor tyrosine kinase (RTK) family.

Graphical abstract: Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling

Supplementary files

Article information

Article type
Concise Article
Submitted
27 Jun 2012
Accepted
09 Sep 2012
First published
11 Sep 2012

Med. Chem. Commun., 2013,4, 228-232

Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling

S. Lee, A. Jo and S. B. Park, Med. Chem. Commun., 2013, 4, 228 DOI: 10.1039/C2MD20169K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements